Shadi Tabibian: Improving Outcomes Through Accurate VWD Subclassification
Shadi Tabibian, Deputy of research at Blood Diseases Research Centers in Iran University of Medical Sciences, shared a post on LinkedIn:
“Type 1C von Willebrand disease has now been formally incorporated into the updated VWD classification following strong endorsement by the ISTH VWF SSC.
This important step recognizes increased VWF clearance as a distinct pathophysiological mechanism and may improve diagnostic precision, treatment selection, clinical research, and patient access to appropriate therapies.
Key clinical implications include:
- VWF half-life of approximately 1–3 hours after DDAVP
- VWFpp/VWF: Ag ratio greater than 3 as a supportive diagnostic marker
- Potentially inadequate or short-lived response to DDAVP
- Consideration of VWF concentrate for major bleeding or surgery
A standardized Type 1C classification provides a clearer framework for diagnosis, registries, clinical trials, and personalized management of patients with von Willebrand disease.”
Other posts featuring Shadi Tabibian on Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda